LIR Life Sciences (PK)【BBCMF】銘柄情報

LIR Life Sciences Corporation (PK) (BBCMF) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.05

( - )

買値

0.0119

売値

1.00

出来高

100

0.05 日の範囲 0.05

0.0136 52 週間の範囲 1.75

時価総額

1.393M

前日終値

0.05

始値

0.05

時刻

100

0.05

最終取引時間

財務取引量

US$ 5

VWAP

0.05

平均取引量 (3 か月)

US$ 12,488

発行済株式数

27,866,957

配当利回り

PER

-2.91

1 株当たり利益 (EPS)

-0.12

歳入

純利益

-2.61M

LIR Life Sciences Corp. operates as biopharmaceutical company that develops transdermal delivery system for obesity and metabolic disorders. The company was incorporated in 2024 and is based in Vancouver, Canada. LIR Life Sciences Corp. operates as biopharmaceutical company that develops transdermal delivery system for obesity and metabolic disorders. The company was incorporated in 2024 and is based in Vancouver, Canada.

セクター

業界

ウェブサイト

www.lirlifesciences.com

本社

Vancouver, Canada

設立

2026

LIR Life Sciences Corporation (PK) is listed in the sector of the その他OTC with ticker BBCMF. The last closing price for LIR Life Sciences (PK) was US$0.05. Over the last year, LIR Life Sciences (PK) shares have traded in a share price range of US$ 0.0136 to US$ 1.75.

LIR Life Sciences (PK) currently has 27,866,957 shares in issue. The market capitalisation of LIR Life Sciences (PK) is US$1.39 million. LIR Life Sciences (PK) has a price to earnings ratio (PE ratio) of -2.91.

LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide

VANCOUVER, BC / ACCESS Newswire / June 17, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN: A41QA9) ("LIR" or...

LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories

VANCOUVER, BC / ACCESS Newswire / May 22, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or...

LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR"...

LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.

VANCOUVER, BC / ACCESS Newswire / April 20, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790) (WKN: A41QA9...

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories

VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9...

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

VANCOUVER, BC / ACCESS Newswire / January 29, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9...

LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies

VANCOUVER, BC / ACCESS Newswire / January 15, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9...

LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform

VANCOUVER, BC / ACCESS Newswire / January 8, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790) (WKN: A41QA9...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0.05	0	0	0	CS
4	-0.2	-80	0.25	0.25	0.05	233	0.10708155	CS
12	-0.2	-80	0.25	0.3461	0.05	296	0.21259676	CS
26	-0.86	-94.5054945055	0.91	1.75	0.05	2910	1.21448807	CS
52	-0.1275	-71.8309859155	0.1775	1.75	0.0136	2247	0.94301155	CS
156	-0.08	-61.5384615385	0.13	1.75	0.0061	22450	0.10701127	CS
260	-0.08	-61.5384615385	0.13	1.75	0.0061	22450	0.10701127	CS

BBCMF - Frequently Asked Questions (FAQ)

What is the current LIR Life Sciences Corporation (PK) share price?

The current share price of LIR Life Sciences Corporation (PK) is US$ 0.05

How many LIR Life Sciences Corporation (PK) shares are in issue?

LIR Life Sciences Corporation (PK) has 27,866,957 shares in issue

What is the market cap of LIR Life Sciences Corporation (PK)?

The market capitalisation of LIR Life Sciences Corporation (PK) is USD 1.39M

What is the 1 year trading range for LIR Life Sciences Corporation (PK) share price?

LIR Life Sciences Corporation (PK) has traded in the range of US$ 0.0136 to US$ 1.75 during the past year

What is the PE ratio of LIR Life Sciences Corporation (PK)?

The price to earnings ratio of LIR Life Sciences Corporation (PK) is -2.91

What is the registered address of LIR Life Sciences Corporation (PK)?

The registered address for LIR Life Sciences Corporation (PK) is 1505 W 2nd Ave, Vancouver, British Columbia, V6J 1H2

What is the LIR Life Sciences Corporation (PK) website address?

The website address for LIR Life Sciences Corporation (PK) is www.lirlifesciences.com

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

LIR Life Sciences Corporation (PK) (BBCMF)

LIR Life Sciences Corporation (PK) (BBCMF) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

LIR Life Sciences Corporation (PK) について

BBCMF 最新ニュース

LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide

LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories

LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules

LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies

LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform

BBCMF - Frequently Asked Questions (FAQ)

BBCMF 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

LIR Life Sciences Corporation (PK) (BBCMF)

LIR Life Sciences Corporation (PK) (BBCMF) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

LIR Life Sciences Corporation (PK) について

BBCMF 最新ニュース

LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide

LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories

LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules

LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies

LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform

BBCMF - Frequently Asked Questions (FAQ)

BBCMF 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する